argenx SE American Depositary Shares ARGX
Analyst Ratings
- Consensus
- Buy — 16 Buy · 2 Hold · 0 Sell (18 analysts)
- Avg. Price Target
- $1144.71 (+13.2% upside)
Key Stats
- Today's Range
- $1001.50 – $1031.18
- 50-Day Range
- $826.45 – $1058.69
- 52-Week Range
- $560.91 – $1058.69
- Volume
- 239K shs
- Average Volume
- 300K shs
- Market Cap
- $65.05 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.26%
- Days to Cover
- 1.00
About argenx SE American Depositary Shares
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Related Stocks
Compare head-to-head: ARGX vs NVDA·ARGX vs AAPL·ARGX vs GOOGL·ARGX vs GOOG
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.